Global Vascular designs and develops a drug-eluting stent delivery system using nanotechnology for lower limb artery disease.
Global Vascular has raised $19.3M in total funding. The most recent round was Series B. The last funding was announced in June 2025.
Global Vascular's investors include Mitsubishi UFJ Capital, Tanaka Kikinzoku Group, MITSUI SUMITOMO INSURANCE Venture Capital (MSIVC), Fast Track Initiative, Inc., TUSIC.
Global Vascular is headquartered in Tokyo, Japan.
Global Vascular designs and develops a drug-eluting stent delivery system using nanotechnology for lower limb artery disease.
Global Vascular is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Global Vascular — Funding & Investors." VCBacked, June 30, 2025, https://www.vcbacked.co/company/global-vascular. Accessed August 15, 2026.
VCBacked. (2025). Global Vascular — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/global-vascular
{{cite web |title=Global Vascular — Funding & Investors |url=https://www.vcbacked.co/company/global-vascular |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated